Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Oklahoma Medical Research Foundation Patents
Assignee:
Oklahoma Medical Research Foundation
Address:
Oklahoma City, OK
No. of patents:
157
Patents:


1 2 3 4










Patent Number Title Of Patent Date Issued
RE36594 Spin trap nitronyl hindered phenols February 29, 2000
The invention is the use of nitronyl substituted hindered phenols as antioxidants in therapeutic applications. In the preferred embodiment the compositions have the general formula: ##STR1## Wherein R1 is hydrogen, an alkyl or an aryl and R2 is an alkyl or an aryl; R.sub.3 is an
RE35213 Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration April 16, 1996
Compositions containing PBN, or active derivatives thereof, in a suitable pharmaceutical carrier for administration to a patient, are disclosed for treating or preventing gastric ulceration caused by ingestion of non-steroidal anti-inflammatories. Based on animal studies, the dosage is
RE35112 Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage December 5, 1995
Compositions for treating tissue damage from ischemia contain PBN, or active derivatives thereof, which are active during ischemia in preventing ATP depletion of the cells which predisposes them to subsequent injury during reperfusion, and which are active during reperfusion as oxygen
8563305 Rapid generation of antibodies October 22, 2013
High efficient methods for producing an antibody molecule that binds an antigen are described. The methods include obtaining a population of PBMC enriched for CD19.sup.highCD3.sup.negCD20.sup.low to negCD38.sup.highCD27.sup.high cells from a mammal exposed to an antigen from sample o
8153766 Monoclonal antibodies against activated protein C April 10, 2012
The present invention provides monoclonal antibodies that selectively bind to and inhibit activated protein C without binding to or inhibiting unactivated protein C. Other antibodies inhibit both activated protein C and activation of unactivated protein C. Methods of treatment employing
8084255 Stem cells treated by in vitro fucosylation and methods of use December 27, 2011
A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an .alpha.1,3-fucosyltransferase, e.g., .alpha.1,3-fucosyltransferase VI, is used in vitro to trea
8008013 Predicting and diagnosing patients with autoimmune disease August 30, 2011
The present invention provides methods for the prediction and diagnosis of autoimmune diseases, including Systemic Lupus Erythematosus, using single nucleotide polymorphism in TNFAIP3 (A20).
7989597 Immunogenic memapsin 2 .beta.-secretase peptides and methods of use August 2, 2011
This application pertains to antibodies which specifically bind to immunogenic memapsin 2.beta.-secretase peptides for use in the treatment of Alzheimer's disease and memapsin 2.beta.-secretase disorders. The application also pertains to immunogenic compositions comprising memapsin 2
7919577 Adrenocorticotropic hormone analogs and related methods April 5, 2011
ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal m
7829669 Catalytically active recombinant memapsin and methods of use thereof November 9, 2010
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs
7816327 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester October 19, 2010
It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison
7794732 Anthrax compositions and methods of use and production September 14, 2010
Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing
7776591 Hematopoietic stem cells treated by in vitro fucosylation and methods of use August 17, 2010
A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an .alpha.1,3-fucosyltransferase, e.g., .alpha.1,3-fucosyltransferase VI, is used in vitro to trea
7683055 Lanthionine-related compounds for the treatment of inflammatory diseases March 23, 2010
The present invention provides compositions comprising lanthionine ketimine derivatives and thiomorpholine dicarboxylic acid derivatives, as well as processes for the preparation of such compounds. The invention also concerns the use of lanthionine, lanthionine ketimine (LK), LK deri
7678760 Inhibitors of Memapsin 2 and use thereof March 16, 2010
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined. The substrate and subsite specificity information was used to design substrate analogs
7659289 Hydroxyethylene-based .beta.-secretase inhibitors and use thereof February 9, 2010
The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.
7655622 Composition and method for regulation of body weight and associated conditions February 2, 2010
Methods for regulating body weight and/or regulating weight gain are provided herein. The methods are useful, for instance, for treating or preventing obesity. Specifically, methods of administering varying levels of various alpha melanocyte stimulating hormone (.alpha.-MSH) analog c
7592003 Regulation of toll-like receptors on stem cells September 22, 2009
The discovery of Toll-like receptors (TLRs) on the surface of hematopoietic cells provides new methods for the stimulation and differentiation of various classes of progenitor cells. TLR2 and TLR4 agonists (natural ligands, mimetics, antibodies) are particularly useful in these metho
7504420 Compounds which inhibit beta-secretase activity and methods of use March 17, 2009
The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating Alzheimer's disease.
7444014 Extended depth of focus microscopy October 28, 2008
Imaging techniques. The focus of an imaging device is varied while acquiring an image of an object. The resulting blurred image is deconvolved to generate, in one embodiment, a two-dimensional projection image of three dimensions of the object.
7410642 Assays and therapies for latent viral infection August 12, 2008
Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells
7332334 Hematopoietic stem cells treated by in vitro fucosylation and methods of use February 19, 2008
A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an .alpha.1,3-fucosyltransferase, e.g., .alpha.1,3-fucosyltransferase VI, is used in vitro to trea
7291333 Blockade of protein C activation reduces microvascular surgical blood loss November 6, 2007
A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma.
7288527 Inhibition of allergic contact dermatitis by N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester October 30, 2007
It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) and/or one of its lower alkyl derivatives can be used to treat allergic contact dermatitis associated with irritating oils such as catechol-containing plant-derived antigens such as poison ivy, poison
7276341 Methods and reagents for diagnosis of autoantibodies October 2, 2007
A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B' polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patient
7273855 Use of prohibitin RNA in treatment of cancer September 25, 2007
It has now been found that the introduction of single stranded oligonucleotides of DNA or RNA, particularly RNA transcribed from portions of wild type prohibitin 3'UTR, into tumors leads to arrested cell proliferation. Significant reduction in the size of primary tumors has been obse
7273613 Diagnostics and therapy of Epstein-Barr virus in autoimmune disorders September 25, 2007
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease.
7259251 3' UTR of the human prohibitin gene August 21, 2007
The 3' untranslated region of the human prohibitin gene has been isolated for use in a cancer susceptibility screen and as a therapeutic agent for the treatment of cancer.
7247453 Calcium binding recombinant antibody against protein C July 24, 2007
A Ca.sup.2+ dependent recombinant antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the Protein C has been constructed. The antibody does not bind to Activated Protein C and can be used to inhibit activation o
7244708 Inhibitors of memapsin 2 and use thereof July 17, 2007
Methods for the production of purified, catalytically active, recombinant memapsin 2 have been developed. The substrate and subsite specificity of the catalytically active enzyme have been determined and were used to design substrate analogs of the natural -2 substrate that can inhibit t
7192715 Diagnostics and therapy of epstein-barr virus in autoimmune disorders March 20, 2007
Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease.
7169573 Method for monitoring coagulability and hypercoagulable states January 30, 2007
The assay of soluble endothelial protein C receptor (sEPCR) is useful to monitor effective thrombin levels and a hypercoagulable state. An assay for sEPCR is therefore useful to monitor ongoing effectiveness of anticoagulant therapy. A sEPCR ELISA assay is particularly useful for thi
7166568 Compositions and methods to inhibit formation of the C5b-9 complex of complement January 23, 2007
Compounds modulating CD59 mediated complement activity, compositions including these compounds, and methods of making and using the compounds are disclosed, which are based on the identification of the hu CD59 amino acid residues which serve as the binding site for CD59-C9 interactions.
7119166 Universal procedure for refolding recombinant proteins October 10, 2006
A universal folding method that has been demonstrated to be effective in refolding a variety of very different proteins expressed in bacteria as inclusion bodies has been developed. Representative proteins that can be dissolved and refolded in biologically active form, with the native
7094538 Diagnostic assay for cancer susceptibility August 22, 2006
The lifetime probability of a person developing cancer can now be determined based on an allelic variation found in the 3'UTR of the prohibitin gene. The probability is dependent on the sequence of the 3'UTR at position 729, i.e., whether there is a thymine (T) or a cytosine (C) or b
7078173 Assays and therapies for latent viral infection July 18, 2006
Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells
7063843 Cloning and regulation of an endothelial cell protein C/activated protein C receptor June 20, 2006
Human protein C and activated protein C were shown to bind to endothelium specifically, selectively and saturably (Kd=30 nM, 7000 sites per cell) in a Ca.sup.2+ dependent fashion. Expression cloning revealed a 1.3 kb cDNA that coded for a novel type I transmembrane glycoprotein capable o
7011956 Thrombotic episode risk assays using oxidized phospholipids March 14, 2006
An assay to assess thrombotic risk in which oxidized lipids comprising phospholipids are utilized as a membrane source in a clotting assay and the results compared to an assay in which unoxidized phospholipid is used as a membrane source in the presence and absence of activated protein C
6989241 Assay for rapid detection of human activated protein C and highly specific monoclonal antibody t January 24, 2006
A highly specific monoclonal antibody, produced by a hybridoma cell has been found. A new assay, highly specific for activated protein C (APC) has been developed which will permit rapid determination of APC levels in clinical situations.
6953568 Targeting of molecules to large vessel endothelium using EPCR October 11, 2005
Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These molecules include antibodi
6919374 Viscosity modulating substance and use thereof July 19, 2005
It has now been found that N-L-alpha-aspartyl-L-phenylalanine 1-methyl ester (APM) lowers whole blood viscosity in patient, including those suffering from sickle cell disease and plasma cell dyscrasias. Upon in vivo APM treatment patients experienced a significant lowering of whole b
6916654 Universal donor cells July 12, 2005
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e.,
6897287 Ro/SSA peptide reagents for diagnosis of autoantibodies May 24, 2005
A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B' polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patient
6890726 Method for selecting recombinase variants with altered specificity May 10, 2005
Disclosed are variants of Cre recombinase that have broadened specificity for the site of recombination. Specifically, the disclosed variants mediate recombination between sequences other than the loxP sequence and other lox site sequences on which wild type Cre recombinase is active. In
6858709 Component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase February 22, 2005
Rbx1, an evolutionarily conserved Cullin-interacting RING-H2 finger protein, has been discovered. Mammalian Rbx1 has been identified as a component of the CUL2-containing VHL complex. An Rbx1 homolog from S. cerevisiae has also been identified as a subunit and activator of the Cdc53-
6838432 Treatment of sepsis with TAFI January 4, 2005
A method for inhibiting and for reversing the dysfunctional response of vascular endothelial cells to an inflammatory stimulus in a subject in need of such therapy has been developed in which an effective amount of a pharmaceutical composition comprising thrombin-activatable fibrinolysis
6838263 Targeted fusion proteins and methods for the characterization of cellular membrane domains January 4, 2005
Cell membranes containing glycolipid-enriched membrane (GEM) and non-glycolipid-enriched membrane (non-GEM) domains are targeted using fusion proteins that are anchored in the cell membrane. Fusion proteins to target GEM (or non-GEM) domains are comprised of a selected fluorescent po
6716810 Composition and method for regulation of body weight and associated conditions April 6, 2004
Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of circulating proopiomelanocortin peptides or analogs thereof
6642008 Assays and therapies for latent viral infection November 4, 2003
Compositions that bind specific viral proteins expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor lat
6641813 Methods and reagents for diagnosis of autoantibodies November 4, 2003
A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B' polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patient
1 2 3 4

 
 
  Recently Added Patents
Interferer region identification using image processing
Efficient paging in a wireless communication system
Atmospheric treater with roller confined discharge chamber
Performance venue with dynamic mechanical load management system and method
Electronic badge
Method and apparatus for reducing cost of optical amplification in a network
Tool bag with removable tool wall
  Randomly Featured Patents
Scanner set-up simulation apparatus
Metal tear off cap
Method and system for modeling external volume changes within an acoustic echo canceller
Synthesis of oligosilazane-containing compounds for the production of a ceramic-like material
Combined keypad and dimmer
Perfume bottle with closure
Laser applying apparatus
Rigid boat cover
Void free oxide fill for interconnect spaces
License plate holder